Clinical Trial Update: Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating safety and efficacy of botulinum toxin A (BotoxA) for neurogenic bladder in Parkinson's disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurogenic Bladder
• Parkinson Disease

Drugs mentioned

• BotoxA (botulinum toxin type A)

Snippet

Sponsor: Stanford University | Conditions: Parkinson's Disease, Neurogenic Bladder | Phase 4 | Status: COMPLETED | Results posted: 2017-03-10